Abingdon Health PLC Director Share Transfer to Trust (3985R)
01 March 2023 - 6:00PM
UK Regulatory
TIDMABDX
RNS Number : 3985R
Abingdon Health PLC
01 March 2023
Abingdon Health plc
("Abingdon Health" or "the Company")
Director Share Transfer to Trust
York, U.K. 1 March 2023: Abingdon Health plc (AIM: ABDX), a
leading international lateral flow contract development and
manufacturing organisation (CDMO), announces that it received
notification on 28 February 2023 that Dr Chris Hand, Non-executive
Chairman, transferred 3,000,000 ordinary shares of 0.025 pence each
in the Company ("Ordinary Shares") from his personal account into
The CW Hand 2023 Settlement, a discretionary trust in which Dr Hand
is a trustee. Dr Hand retains an additional 10,027,667 Ordinary
Shares outside of the trust.
Dr Hand has advised the Company that he has no intention of
selling Ordinary Shares, either from those held inside the trust or
those held outside of the trust.
Following this transaction the percentage of Ordinary Shares
that Dr Hand retains outside of the trust combined with those for
which he is a trustee remains at 10.7 per cent.
Further details are set out in the PDMR form below, made in
accordance with the Market Abuse Regulation (EU) No. 596/2014 which
is part of UK law by virtue of the European Union (Withdrawal) Act
2018.
Enquiries
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development
and manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an
ecommerce platform that offers a range of self-tests to empowers
consumers to manage their own health and wellbeing. The Abingdon
Simply Test ecommerce site offers consumers a range of information
to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland such
as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Chris Hand
--------------------------------------------- -------------------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------------------
a) Position/status Non-executive Chairman
--------------------------------------------- -------------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------------- -------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------------------
a) Name Abingdon Health plc
--------------------------------------------- -------------------------------------------------------------
b) LEI 213800XFI4WV3FBILO20
--------------------------------------------- -------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.025 pence each
financial instrument,
type of instrument
Identification code GB00BLF79J41
b) Nature of the transaction Transfer of 3,000,000 Ordinary Shares
to The CW Hand 2023 Settlement Trust
--------------------------------------------- -------------------------------------------------------------
c) Price(s) and volume(s) Price Volume
---------------------------------------------- ----------
N/A 3,000,000
------------------------------------------------------------------------------------------------- ----------
d) Aggregated information n/a single transaction
e) Date of the transaction 28 February 2023
--------------------------------------------- -------------------------------------------------------------
f) Place of the transaction Off market
--------------------------------------------- -------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUWABRORUUUAR
(END) Dow Jones Newswires
March 01, 2023 02:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jul 2023 to Jul 2024
